In8Bio INAB
NASDAQ INAB
$1.04 +0.05 (+4.55%)
As of: Oct 23, 2026 · 3:59 PM EDT

In8Bio (INAB) Amortization of Deferred Charges (2021 - 2026)

Updated

Analysis

In8Bio (INAB) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 In8Bio 20.25 Mn -58.10 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 62,000.00
Mar 31, 2026 108,000.00
Dec 31, 2025 119,000.00
Sep 30, 2025 126,000.00
Jun 30, 2025 286,000.00
Mar 31, 2025 240,000.00
Dec 31, 2024 234,000.00
Sep 30, 2024 228,000.00
Jun 30, 2024 193,000.00
Mar 31, 2024 204,000.00
Dec 31, 2023 215,000.00
Sep 30, 2023 238,000.00
Jun 30, 2023 230,000.00
Mar 31, 2023 188,000.00
Dec 31, 2022 120,000.00
Sep 30, 2022 90,000.00
Jun 30, 2022 102,000.00
Mar 31, 2022 149,000.00
Dec 31, 2021 145,000.00
Sep 30, 2021 141,000.00
API Access

In8Bio Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=INAB&period=max&api_key=YOUR_API_KEY